SYL1801

Sylentis, S.A. · Phase 2 active Small molecule

At a glance

Generic name	SYL1801
Sponsor	Sylentis, S.A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) (PHASE2)
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYL1801 CI brief — competitive landscape report
SYL1801 updates RSS · CI watch RSS
Sylentis, S.A. portfolio CI